Information Provided By:
Fly News Breaks for July 23, 2019
RHHBY, MSFT, ADPT
Jul 23, 2019 | 07:27 EDT
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
News For ADPT;MSFT;RHHBY From the Last 2 Days
MSFT
Mar 27, 2024 | 15:57 EDT
Welcome to "#SocialStocks," The Fly's weekly recap of Wall Street's reactions to social media stock news. GOVERNMENT SCRUTINY: The Biden... To see the rest of the story go to thefly.com. See Story Here
MSFT
Mar 26, 2024 | 13:49 EDT
Microsoft Gaming CEO Phil Spencer told Polygon in an interview during the annual Game Developers Conference that he doesn't just want Xbox games on other consoles, but also wants other game retailers, such as Itch.io and the Epic Games Store on Xbox platforms as well. "Consider our history as the Windows company," Spencer said. "Nobody would blink twice if I said, 'Hey, when you're using a PC, you get to decide the type of experience you have... There's real value in that." Reference Link
MSFT
Mar 26, 2024 | 12:26 EDT
"Game On" is The Fly's weekly recap of the stories powering up or beating down video game stocks. NEW RELEASES: While... To see the rest of the story go to thefly.com. See Story Here